Home > Publications database > The underestimated preventive effects of flexible sigmoidoscopy screening: re-analysis and meta-analysis of randomized trials. > print

001     289654
005     20241121143917.0
024 7 _ |a 10.1007/s10654-024-01120-w
|2 doi
024 7 _ |a pmid:38642235
|2 pmid
024 7 _ |a 0393-2990
|2 ISSN
024 7 _ |a 1573-7284
|2 ISSN
024 7 _ |a altmetric:162810687
|2 altmetric
037 _ _ |a DKFZ-2024-00836
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Brenner, Hermann
|0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|b 0
|e First author
245 _ _ |a The underestimated preventive effects of flexible sigmoidoscopy screening: re-analysis and meta-analysis of randomized trials.
260 _ _ |a Dordrecht [u.a.]
|c 2024
|b Springer Science + Business Media B.V.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1725441862_26264
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:C070#LA:C070# / 2024 Jul;39(7):743-751
520 _ _ |a Flexible sigmoidoscopy (FS), which is less invasive, resource intensive and costly than colonoscopy, is among the recommended screening options for colorectal cancer (CRC). Four large randomized trials consistently reported statistically significant, albeit modest effects of screening by FS on CRC incidence. However, their effect estimates included cancers that were already prevalent at recruitment and could not have been prevented by screening. We performed a re-analysis and meta-analysis of two of the trials (including the largest one) to estimate reduction of truly incident cases by a single FS offered between 55 and 64 years of age among the 'at risk study population' without prevalent CRC at recruitment. In meta-analyses of data reported after more than 15 years of follow-up, relative risk (95% CI) in intention-to-screen and per-protocol analyses were 0.71 (0.66-0.76) and 0.59 (0.55-0.65) for any CRC, and 0.52 (0.47-0.57) and 0.34 (0.30-0.39) for distal CRC, respectively. These results indicate much stronger effects than those suggested by the original reports and imply that a single screening FS can prevent approximately two out of three distal incident CRC cases within 15 + years of follow-up.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Colorectal cancer
|2 Other
650 _ 7 |a Flexible sigmoidoscopy
|2 Other
650 _ 7 |a Incidence
|2 Other
650 _ 7 |a Risk
|2 Other
650 _ 7 |a Screening
|2 Other
650 _ 7 |a Trials
|2 Other
700 1 _ |a Heisser, Thomas
|0 0000-0002-1348-3350
|b 1
700 1 _ |a Cardoso, Rafael
|0 0000-0002-9155-7415
|b 2
700 1 _ |a Hoffmeister, Michael
|0 P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f
|b 3
|e Last author
773 _ _ |a 10.1007/s10654-024-01120-w
|0 PERI:(DE-600)2004992-4
|n 7
|p 743-751
|t European journal of epidemiology
|v 39
|y 2024
|x 0393-2990
856 4 _ |u https://inrepo02.dkfz.de/record/289654/files/s10654-024-01120-w.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/289654/files/s10654-024-01120-w.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:inrepo02.dkfz.de:289654
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 0000-0002-1348-3350
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 0000-0002-9155-7415
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2024
915 _ _ |a National-Konsortium
|0 StatID:(DE-HGF)0430
|2 StatID
|d 2023-08-25
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2023-08-25
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2023-08-25
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR J EPIDEMIOL : 2022
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-25
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-08-25
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b EUR J EPIDEMIOL : 2022
|d 2023-08-25
920 2 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 0
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
920 0 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21